11 Aug

Pharma should make good use of the UPC from the beginning, says Bayer’s head of IP

Though caution over the new pan-EU patent litigation system is required, in-house and private practice experts tell IAM that the UPC is likely to prove a boon for pharma and biotech innovators

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth